Cambridge Cognition Holdings PLC Partnership to tackle growing mental health need

TIDMCOG

Cambridge Cognition Holdings PLC

07 June 2018

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Partnership to tackle growing mental health need

The digital neuroscience company Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce a new strategic collaboration and partnership with the University of Bristol to accelerate the development of novel brain health products.

Mental and substance use disorders are now the leading cause of disability worldwide, resulting in 23% of all years lost with a global economic loss of a trillion US dollars every year(1) .

New scalable tools are needed to measure mental health objectively and to enable clinicians to better diagnose and monitor patients.

Cambridge Cognition's digital health products exemplify how new technologies can transform clinical research and health, while the team at the University of Bristol, led by Professor Marcus Munafò, brings expertise in mental health and addiction along with an established network of patient groups and clinicians.

The creation of this collaboration will enable the Company to run in-patient studies with the University and accelerate the development of new software applications to help clinicians address the global need in mental health conditions.

Professor Marcus Munafò, Professor of Biological Psychology, University of Bristol said: "This is an exciting opportunity to rapidly translate our research into clinical practice and patient benefit. We have worked with Cambridge Cognition for several years and this partnership allows us to extend this work and build on their experience of digital neuroscience."

Dr Jenny Barnett, Chief Scientific Officer, Cambridge Cognition said: "We are delighted to extend and formalise our relationship with the talented team at the University of Bristol. Working more closely will enable us to build a pipeline of novel, evidence-based and usable tools to better measure and monitor mental health across all ages groups and accelerate our ability to validate our digital health apps in a clinical setting."

Sources:

(1) World Health Organization (WHO) March 30, 2017

Enquiries

 
 Cambridge Cognition Holdings PLC 
  Steven Powell, Chief Executive Officer         Tel: [phone] 
  Noah Konig, Director of Marketing              [e-mail] 
 finnCap Ltd (NOMAD and Joint Broker)          Tel: [phone] 
  Geoff Nash / Simon Hicks                      (Corporate Finance) 
  Alice Lane                                    (Corporate Broking) 
 Dowgate Capital Stockbrokers Limited (Joint   Tel: [phone] 
  Broker) 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)        Tel: [phone] 
  Graham Herring / Miles Nolan / Zach Cohen 
 

About Cambridge Cognition

Cambridge Cognition is a digital neuroscience company developing software products to better understand, detect and treat brain health conditions. The company's cognitive technologies are used to accelerate the research and development of new treatments, enhance understanding of the brain and accurately assess cognitive health in patients worldwide.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRADMGGVKVFGRZM

(END) Dow Jones Newswires

June 07, 2018 02:01 ET (06:01 GMT)